2-Substituted 4-, 5-, and 6-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones and 2-substituted 4,5-bis[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones as potent platelet aggregation inhibitors: Design, synthesis, and SAR studies
regioisomeric 2-substituted pyridazin-3(2H)-ones containing a 3-oxo-3-phenylprop-1-en-1-yl fragment at either position 4, 5 or 6 and 2-substituted pyridazin-3(2H)-ones containing the same fragment both at positions 4 and 5 have been synthesized and evaluated as antiplatelet agents. The study allows the identification of a new highly potent plateletaggregationinhibitor (4c).
PYRIDAZINONE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS
申请人:Chiesi Farmaceutici S.p.A.
公开号:EP3191491B1
公开(公告)日:2019-09-04
US9745308B2
申请人:——
公开号:US9745308B2
公开(公告)日:2017-08-29
[EN] PYRIDAZINONE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDAZINONE À TITRE D'INHIBITEURS DE PHOSPHOINOSITIDE 3-KINASES
申请人:CHIESI FARMA SPA
公开号:WO2016038140A1
公开(公告)日:2016-03-17
The invention relates to compounds of formula (I) inhibiting phosphoinositide 3-kinases (PI3K), to pharmaceutical compositions comprising them, and to therapeutic uses thereof in the treatment of disorders associated with PI3K enzymes such as respiratory diseases, allergic diseases, autoimmune diseases or inflammatory disorders.